Enlivex Therapeutics (ENLV) Short Interest Ratio & Short Volume $1.05 +0.02 (+1.94%) Closing price 04:00 PM EasternExtended Trading$1.05 0.00 (0.00%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enlivex Therapeutics Short Interest DataEnlivex Therapeutics (ENLV) has a short interest of 196,500 shares, representing 0.95% of the float (the number of shares available for trading by the public). This marks a -33.25% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.2, indicating that it would take 1.2 days of the average trading volume of 256,951 shares to cover all short positions.Current Short Interest196,500 sharesPrevious Short Interest294,400 sharesChange Vs. Previous Month-33.25%Dollar Volume Sold Short$292.79 thousandShort Interest Ratio1.2 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares23,650,000 sharesShort Percent of Float0.95%Today's Trading Volume887,884 sharesAverage Trading Volume256,951 sharesToday's Volume Vs. Average346% Short Selling Enlivex Therapeutics? Sign up to receive the latest short interest report for Enlivex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENLV Short Interest Over TimeENLV Days to Cover Over TimeENLV Percentage of Float Shorted Over Time Enlivex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025196,500 shares $292.79 thousand -33.3%0.9%1.2 $1.49 7/15/2025294,400 shares $362.11 thousand +51.7%N/A3.6 $1.23 6/30/2025194,100 shares $217.39 thousand +157.8%0.9%2.6 $1.12 6/15/202575,300 shares $68.15 thousand -23.6%0.4%1.1 $0.91 5/31/202598,600 shares $94.99 thousand -18.8%0.5%1.3 $0.96 5/15/2025121,400 shares $125.04 thousand -11.3%0.6%1 $1.03 4/30/2025136,900 shares $139.64 thousand +43.1%N/A1.1 $1.02 4/15/202595,700 shares $85.32 thousand -8.3%0.5%0.8 $0.89 3/31/2025104,400 shares $101.29 thousand -17.9%0.6%0.8 $0.97 3/15/2025127,100 shares $155.06 thousand +11.0%0.7%0.9 $1.22 Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/2025114,500 shares $137.40 thousand +8.9%0.6%0.5 $1.20 2/15/2025105,100 shares $110.36 thousand -11.5%0.6%0.5 $1.05 1/31/2025118,800 shares $130.68 thousand -3.4%N/A0.6 $1.10 1/15/2025123,000 shares $141.45 thousand -1.8%N/A0.5 $1.15 12/31/2024125,200 shares $146.48 thousand -41.2%N/A0.5 $1.17 12/15/2024212,900 shares $255.48 thousand -0.9%N/A0.9 $1.20 11/30/2024214,800 shares $244.87 thousand +116.5%N/A0.9 $1.14 11/15/202499,200 shares $106.14 thousand -38.0%N/A0.7 $1.07 10/31/2024160,100 shares $216.14 thousand +58.7%N/A1.4 $1.35 10/15/2024100,900 shares $156.40 thousand -3.5%N/A1.1 $1.55 9/30/2024104,600 shares $175.73 thousand -23.1%N/A1.4 $1.68 9/15/2024136,100 shares $213.68 thousand +43.9%N/A1.9 $1.57 8/31/202494,600 shares $122.98 thousand +26.6%N/A1.9 $1.30 8/15/202474,700 shares $91.13 thousand -11.7%N/A1.3 $1.22 7/31/202484,600 shares $113.36 thousand -27.4%N/A1.4 $1.34 7/15/2024116,500 shares $164.27 thousand -0.6%N/A1.6 $1.41 6/30/2024117,200 shares $166.42 thousand -16.8%N/A0.7 $1.42 6/15/2024140,800 shares $205.57 thousand -10.5%N/A0.8 $1.46 5/31/2024157,300 shares $213.93 thousand -31.8%N/A0.9 $1.36 5/15/2024230,600 shares $327.45 thousand -12.4%N/A1.3 $1.42 4/30/2024263,200 shares $439.54 thousand -5.6%N/A1.5 $1.67 4/15/2024278,700 shares $362.31 thousand +17.9%N/A1.6 $1.30 3/31/2024236,400 shares $895.96 thousand -9.6%N/A2.7 $3.79 3/15/2024261,500 shares $1.07 million +15.4%N/A2.4 $4.11 2/29/2024226,600 shares $703.59 thousand +51.2%N/A2.2 $3.11 2/15/2024149,900 shares $481.18 thousand -6.6%N/A1.6 $3.21 1/31/2024160,500 shares $449.40 thousand -13.7%N/A1.9 $2.80 1/15/2024185,900 shares $533.53 thousand +32.5%N/A2.3 $2.87 12/31/2023140,300 shares $378.81 thousand +36.0%N/A1.8 $2.70 12/15/2023103,200 shares $145.51 thousand -6.3%N/A1.9 $1.41Out of 18,347 Cryptocurrencies... This is the ONLY One (Ad)The $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol quietly prints $1 million in fees every single day.Discover our #1 crypto recommendation here now >> 11/30/2023110,100 shares $202.58 thousand -0.9%N/A3.5 $1.84 11/15/2023111,100 shares $194.43 thousand -6.2%N/A3.6 $1.75 10/31/2023118,400 shares $157.47 thousand +13.1%N/A3.9 $1.33 10/15/2023104,700 shares $147.63 thousand -8.1%N/A4.1 $1.41 9/30/2023113,900 shares $179.96 thousand +4.4%N/A4.5 $1.58 9/15/2023109,100 shares $206.20 thousand +3.4%N/A4.2 $1.89 8/31/2023105,500 shares $252.15 thousand -9.3%N/A4.8 $2.39 8/15/2023116,300 shares $303.54 thousand +2.4%N/A5.1 $2.61 7/31/2023113,600 shares $290.82 thousand +8.6%N/A4.9 $2.56 7/15/2023104,600 shares $248.95 thousand +2.5%N/A4.8 $2.38 6/30/2023102,100 shares $268.25 thousand -20.2%N/A3.6 $2.63 6/15/2023128,000 shares $362.24 thousand +5.6%N/A3.6 $2.83 5/31/2023121,200 shares $316.33 thousand -5.8%N/A3.5 $2.61 5/15/2023128,700 shares $359.07 thousand -1.2%N/A3.8 $2.79 4/30/2023130,200 shares $369.77 thousand -4.6%N/A3.7 $2.84 4/15/2023136,400 shares $396.92 thousand -15.7%N/A3.6 $2.91 3/31/2023161,700 shares $588.59 thousand +0.5%N/A4.3 $3.64 3/15/2023160,900 shares $577.63 thousand -1.3%N/A5.9 $3.59 2/28/2023163,000 shares $652 thousand +0.9%N/A5.7 $4.00 2/15/2023161,500 shares $673.46 thousand -8.8%N/A5.5 $4.17 1/31/2023177,100 shares $775.70 thousand -2.9%N/A5.8 $4.38 1/15/2023182,300 shares $796.51 thousand -4.8%N/A6.9 $4.37 12/30/2022191,400 shares $753.64 thousand -0.5%N/A7.8 $3.94 12/15/2022192,400 shares $779.22 thousand -11.5%N/A9.2 $4.05 11/30/2022217,500 shares $997.00 thousand +16.9%N/A9 $4.58 11/15/2022186,000 shares $894.66 thousand +0.1%N/A6.9 $4.81 10/31/2022185,800 shares $797.08 thousand -3.8%N/A6.6 $4.29 10/15/2022193,100 shares $805.23 thousand +1.2%N/A5.4 $4.17 9/30/2022190,900 shares $811.33 thousand +4.5%N/A4.4 $4.25 9/15/2022182,700 shares $959.18 thousand -5.4%N/A3.9 $5.25 8/31/2022193,100 shares $1.01 million -7.0%N/A4.2 $5.25 8/15/2022207,700 shares $1.08 million -9.5%N/A4.4 $5.22 7/31/2022229,600 shares $975.80 thousand -8.4%N/A4 $4.25 7/15/2022250,600 shares $1.23 million -9.8%N/A3.8 $4.91 6/30/2022277,700 shares $1.26 million -2.3%N/A3.5 $4.52 6/15/2022284,300 shares $1.16 million -0.3%N/A3.5 $4.07 5/31/2022285,000 shares $1.43 million -9.2%N/A3.5 $5.01 5/15/2022313,900 shares $1.34 million -9.6%N/A4.1 $4.28 4/30/2022347,200 shares $1.98 million -3.9%N/A4.7 $5.69 4/15/2022361,300 shares $2.67 million +15.0%N/A5.9 $7.39 3/31/2022314,200 shares $1.76 million -2.2%N/A5.3 $5.59 3/15/2022321,300 shares $1.63 million -10.4%N/A5.3 $5.06 2/28/2022358,500 shares $1.92 million -4.0%N/A4.9 $5.35 2/15/2022373,500 shares $1.99 million +2.8%N/A4.7 $5.34 1/31/2022363,200 shares $1.94 million +8.2%N/A4.2 $5.34 1/15/2022335,700 shares $1.97 million -8.3%N/A3.7 $5.87 12/31/2021365,900 shares $2.29 million +0.1%N/A4.2 $6.25 12/15/2021365,400 shares $2.40 million -3.6%N/A4.4 $6.56 11/30/2021379,000 shares $2.65 million +7.0%N/A5 $7.00 11/15/2021354,200 shares $2.91 million +9.9%N/A3.5 $8.21Out of 18,347 Cryptocurrencies... This is the ONLY One (Ad)The $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol quietly prints $1 million in fees every single day.Discover our #1 crypto recommendation here now >> 10/29/2021322,200 shares $2.65 million +4.5%N/A1 $8.24 10/15/2021308,300 shares $2.86 million -13.0%N/A0.9 $9.28 9/30/2021354,300 shares $3.50 million -8.0%N/A1.1 $9.88 9/15/2021385,200 shares $4.21 million -8.0%N/A1.2 $10.92 8/31/2021418,500 shares $5.80 million +114.2%N/A1.3 $13.86 8/13/2021195,400 shares $1.99 million +38.0%N/A0.7 $10.17 7/30/2021141,600 shares $1.08 million No Change1.2%2.1 $7.60 7/15/2021141,600 shares $1.07 million +0.9%1.2%1.8 $7.54 6/30/2021140,400 shares $1.25 million +4.0%1.2%1.6 $8.90 6/15/2021135,000 shares $1.32 million +14.9%1.1%1.5 $9.80 5/28/2021117,500 shares $1.10 million -28.6%1.0%1.1 $9.37 5/14/2021164,500 shares $1.42 million +26.4%N/A1.1 $8.61 4/30/2021130,100 shares $1.57 million +94.2%N/A0.3 $12.10 4/15/202167,000 shares $725.61 thousand -18.8%N/A0.2 $10.83 3/31/202182,500 shares $874.50 thousand -17.6%N/A0.2 $10.60 3/15/2021100,100 shares $1.44 million +5.2%1.0%0.2 $14.40 2/26/202195,200 shares $1.44 million +64.4%1.1%0.2 $15.11 2/12/202157,900 shares $1.22 million -76.6%0.7%0.1 $21.09 1/29/2021246,900 shares $2.93 million +13.8%3.2%0.7 $11.85 1/15/2021217,000 shares $2.23 million +7.1%2.9%1 $10.29 12/31/2020202,600 shares $1.87 million -24.9%2.7%0.7 $9.22 12/15/2020269,700 shares $2.65 million +165.2%3.5%0.2 $9.83 11/30/2020101,700 shares $876.65 thousand -38.2%1.3%0.1 $8.62 11/15/2020164,600 shares $1.53 million -13.1%2.2%0.1 $9.28 10/30/2020189,500 shares $2.23 million -53.7%2.5%0.2 $11.75 10/15/2020408,900 shares $5.41 million +1,497.3%5.4%0.4 $13.23 9/30/202025,600 shares $152.06 thousand +22.5%0.3%0 $5.94 9/15/202020,900 shares $108.26 thousand -57.1%0.3%0.3 $5.18 8/31/202048,700 shares $252.75 thousand +429.4%0.6%0.5 $5.19 ENLV Short Interest - Frequently Asked Questions What is Enlivex Therapeutics' current short interest? Short interest is the volume of Enlivex Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 196,500 shares of ENLV short. 0.95% of Enlivex Therapeutics' shares are currently sold short. Learn More on Enlivex Therapeutics' current short interest. What is a good short interest ratio for Enlivex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENLV shares currently have a short interest ratio of 1.0. Learn More on Enlivex Therapeutics's short interest ratio. Which institutional investors are shorting Enlivex Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enlivex Therapeutics: Group One Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Enlivex Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.95% of Enlivex Therapeutics' floating shares are currently sold short. Is Enlivex Therapeutics' short interest increasing or decreasing? Enlivex Therapeutics saw a decline in short interest in July. As of July 31st, there was short interest totaling 196,500 shares, a decline of 33.3% from the previous total of 294,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enlivex Therapeutics' short interest compare to its competitors? 0.95% of Enlivex Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enlivex Therapeutics: SELLAS Life Sciences Group, Inc. (26.84%), Enanta Pharmaceuticals, Inc. (13.75%), Lifevantage Corporation (23.30%), Nkarta, Inc. (12.43%), Nuvectis Pharma, Inc. (7.66%), Greenwich LifeSciences, Inc. (17.36%), Cardiff Oncology, Inc. (30.68%), Journey Medical Corporation (13.91%), Cellectis S.A. (0.38%), MEI Pharma, Inc. (34.18%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Enlivex Therapeutics stock? Short selling ENLV is an investing strategy that aims to generate trading profit from Enlivex Therapeutics as its price is falling. ENLV shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enlivex Therapeutics? A short squeeze for Enlivex Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENLV, which in turn drives the price of the stock up even further. How often is Enlivex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENLV, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies SELLAS Life Sciences Group Short Squeeze Enanta Pharmaceuticals Short Squeeze Lifevantage Short Squeeze Nkarta Short Squeeze Nuvectis Pharma Short Squeeze Greenwich LifeSciences Short Squeeze Cardiff Oncology Short Squeeze Journey Medical Short Squeeze Cellectis Short Squeeze MEI Pharma Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENLV) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access